ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of the “at the market” equity of its offering plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering program under which Acasti may issue and sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January twenty seven, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares had been sold at prevailing market rates averaging US$1.0747 per share. No securities were sold in the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with extra flexibility in its continuous review process to explore as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription drugs making use of OM3 fatty acids delivered both as totally free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of efficacy as well as safety in lowering triglycerides in individuals with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which are not statements of historical or current truth constitute “forward looking information” within the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, along with other unknown variables that can cause the actual results of Acasti to be materially different from historical outcomes and even from any later results expressed or implied by such forward looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, people are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be forward-looking and uncertain. People are cautioned not to place undue reliance on these forward-looking statements, which speak just as of the day of this press release. Forward-looking statements in that press release include, but aren’t limited to, statements or information concerning Acasti’s strategy, succeeding operations as well as the review of its of strategic options.
The forward looking statements contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor section of Acasti’s site at www.acastipharma.com. Many forward looking statements in that press release exist as of the particular date of this press release.
ACST Stock – Acasti does not undertake to redesign some such forward looking statements whether as a direct result of info which is brand new, future events or even otherwise, except as required by law. The forward-looking claims contained herein are also subject typically to assumptions and risks as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage